Comprehensive Hematology Oncology — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,011,660	17
2024	Research	$386,930	2
2021	Research	$37,817	30

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $1,226,353 6 payments
Merck Sharp & Dohme Corporation $154,129 1 payment
Kyowa Kirin Pharmaceutical Development, Inc $24,100 19 payments
Kyowa Kirin, Inc. $13,717 11 payments
Lantheus Medical Imaging, Inc. $7,500 3 payments
BeiGene USA, Inc. $6,988 1 payment
Pfizer Inc. $3,098 3 payments
Daiichi Sankyo Inc. $522 5 payments

Studies the money was for Research payments · program years 2021–2025

Sunray-01 A Global Pivotal Study in Participants With Kras G12c-Mutant Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Comparing First Line Treatment of Ly3537982 and Pembrolizumab VS Placebo and Pembrolizumab in Those With PD L1 Expression 50% Or Ly3537982 and Pembrolizumab Pemetrexed Platinum VS Placebo and Pembrolizumab Pemetrexed Platinum Regardless of Pd-L1 Expression $1,210,880 4 payments
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received $154,129 1 payment
Kyowa Kirin 2455-002 $37,817 30 payments
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected Or Unresectable Kras G12c-Mutant, Non-Small Cell Lung Cancer - Sunray-02 $14,850 1 payment
Expanded Access Treatment With [Lu-177]-Pnt2002 for Adult Patients With Prostate-Specific Membrane Antigen (Psma)-Positive Metastatic Castration-Resistant Prostate Cancer (Mcrpc) $7,500 3 payments
Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer $6,988 1 payment
A Phase 2B3 Randomized Doubleblind Study to Investigate the Efficacy Safety and Tolerability of Ponsegromab Pf06946860 Compared With Placebo Both With Background Firstline Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma $3,098 3 payments
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected Or Unresectable Kras G12c-Mutant, Non-Small Cell Lung Cancer - Sunray-02 $623 1 payment
Ds1062-328 $522 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.